2015
DOI: 10.1016/j.pnpbp.2014.11.006
|View full text |Cite
|
Sign up to set email alerts
|

Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics

Abstract: In this prospective multicentre, open-label, 6-month study (Paliperidone Palmitate Flexible Dosing in Schizophrenia [PALMFlexS]), tolerability, safety and treatment response with paliperidone palmitate (PP) were explored in patients with acute symptoms of schizophrenia following switching from previously unsuccessful treatment with oral antipsychotics. This pragmatic study was conducted in a large, more representative sample of the general schizophrenia population compared to randomized controlled pivotal tria… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

5
35
0

Year Published

2016
2016
2022
2022

Publication Types

Select...
6
2

Relationship

1
7

Authors

Journals

citations
Cited by 52 publications
(40 citation statements)
references
References 43 publications
5
35
0
Order By: Relevance
“…Several factors may contribute to poor adherence, including clinical symptoms as disorganization, cognitive impairments, poor insight, but also dosing frequency, adverse events, and complexity of the treatment regimen. This is the reason why long-acting injectable (LAI) formulations of antipsychotic medications are a good solution to provide sustained therapeutic plasma concentrations for several weeks, reducing the risk of non-adherence, minimizing relapse rates, and providing long-term clinical benefits [3][4][5][6].…”
Section: Introductionmentioning
confidence: 99%
“…Several factors may contribute to poor adherence, including clinical symptoms as disorganization, cognitive impairments, poor insight, but also dosing frequency, adverse events, and complexity of the treatment regimen. This is the reason why long-acting injectable (LAI) formulations of antipsychotic medications are a good solution to provide sustained therapeutic plasma concentrations for several weeks, reducing the risk of non-adherence, minimizing relapse rates, and providing long-term clinical benefits [3][4][5][6].…”
Section: Introductionmentioning
confidence: 99%
“…The Paliperidone Palmitate Flexible Dosing in Schizophrenia (PALMFlexS) study was a prospective, 6-month, pragmatic, interventional study conducted in a large, more representative sample of patients with schizophrenia than those recruited in the pivotal RCTs (Hargarter et al 2015; Schreiner et al 2015b; Schreiner et al 2014a). The study was designed specifically to reflect more closely real-world clinical situations in which the transition to another antipsychotic is performed in previously unsuccessfully treated patients.…”
Section: Introductionmentioning
confidence: 99%
“…A more recent prospective clinical trial conducted in a more representative sample of patients (i.e., including patients with substance-related disorders) demonstrated symptom improvement associated with PP1M [17]. However, there remains a need to better understand the impact of PP1M specifically within the population of patients with schizophrenia and comorbid substance-related disorders.…”
mentioning
confidence: 99%